Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04313712 · ClinicalTrials.gov registry record
Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure
A clinical trial of Head Injury Trauma and Blast or Combat Exposure, sponsored by Stanford University.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04313712: Active study of Head Injury Trauma and Blast or Combat Exposure, sponsored by Stanford University.
NCT04313712 is a study of Head Injury Trauma and Blast or Combat Exposure that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04313712, a study of Head Injury Trauma and Blast or Combat Exposure, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans with Sequelae of Repeated Blast Exposure.
Primary Outcome
The WHODAS 2.0 is a generic assessment of disability across six domains of functioning including cognition, mobility, self-care, interpersonal relationships, life activities, and community activities. The higher the score, the greater the level of self-reported disability in functioning. Scores from baseline will be compared to scores at the immediate post-treatment.
Conditions Studied
Interventions
- DRUG ibogaine with magnesium treatment
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2025-02 |
What the registry record for NCT04313712 still lists
NCT04313712 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 2 conditions, with Head Injury Trauma appearing as the primary indexed condition, and to 1 intervention - of which ibogaine with magnesium treatment is the first listed.
NCT04313712 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04313712 about?
NCT04313712 is a clinical study titled "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure". A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans with Sequelae of Repeated Blast Exposure.
What is the current status of trial NCT04313712?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2021-11-15. Estimated completion is 2025-02.
What conditions does trial NCT04313712 study?
This clinical trial studies the following conditions: Head Injury Trauma, Blast or Combat Exposure.
What interventions are being tested in trial NCT04313712?
The interventions under investigation include: ibogaine with magnesium treatment (DRUG).
Who is sponsoring clinical trial NCT04313712?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04313712 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Injury Trauma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI